Nystagmus

Nystagmus is an involuntary, rhythmic oscillation of the eyes that can be horizontal, vertical, torsional, or mixed. It may be present from infancy (infantile/early-onset) or acquired later due to neurologic, vestibular, visual, metabolic, or drug-related causes. Patients may have blurred vision, reduced visual acuity, head turns (to use a null point where nystagmus dampens), and, in acquired cases, oscillopsia (illusory movement of the environment). Diagnosis is clinical, guided by a detailed ocular and neurologic examination and targeted testing. Management addresses the underlying cause and may include optical strategies, prism, pharmacologic therapy (mostly off-label), and strabismus surgery to reduce abnormal head posture and improve function.

Key Points

• Nystagmus is a sign, not a diagnosis; etiologies span infantile ocular motor disorders, sensory visual deprivation, vestibular disease, central nervous system lesions, medications, and toxins.
• Infantile nystagmus syndrome (INS) typically lacks oscillopsia and often improves with convergence; acquired nystagmus commonly causes oscillopsia and warrants prompt evaluation for neurologic or vestibular disease.
• Clinical characterization (direction, waveform, Alexander’s law, effect of gaze, fixation, convergence) narrows the differential and guides testing.
• Treat reversible causes (eg, drug toxicity, thiamine deficiency, acute vestibular neuritis). Visual rehabilitation, prisms, and selective surgeries improve function in INS.
• Pharmacologic therapy is condition-specific and largely off-label (eg, baclofen for periodic alternating nystagmus; 4-aminopyridine for downbeat nystagmus; gabapentin or memantine in some infantile/acquired cases).
• Sudden-onset nystagmus with brainstem/cerebellar signs, severe vertigo, new diplopia, or headache is an emergency; evaluate for stroke or posterior fossa pathology.

Anatomy and Physiology

Gaze stability depends on integrated ocular motor systems:

• Vestibulo-ocular reflex (VOR): stabilizes images during head motion.
• Neural integrator (brainstem/cerebellar network): holds eccentric gaze; failure yields gaze-evoked nystagmus.
• Smooth pursuit and saccadic systems: track moving targets and generate rapid refixations.
• Optokinetic system: sustains tracking for large-field motion.
• Foveation periods: brief intervals of minimal retinal slip allow best acuity; altered foveation degrades vision in nystagmus.

Cerebellar nodulus/uvula, flocculus, and brainstem nuclei (vestibular, interstitial nucleus of Cajal) are key modulators; lesions produce characteristic nystagmus patterns.

Etiology

• Infantile/early-onset

  • Infantile nystagmus syndrome (INS; idiopathic/motor).
  • Sensory nystagmus due to reduced afferent input: albinism, foveal hypoplasia, achromatopsia, Leber congenital amaurosis, aniridia, congenital cataract/corneal opacity, optic nerve hypoplasia or atrophy.
  • Latent/manifest latent nystagmus with infantile strabismus (often esotropia).
  • Spasmus nutans (triad: nystagmus, head nodding, torticollis) in infancy; typically self-limited.

• Acquired

  • Peripheral vestibular disorders: vestibular neuritis, Ménière disease, labyrinthitis, vestibular schwannoma.
  • Central lesions: stroke (especially posterior circulation), demyelination (multiple sclerosis), Chiari malformation, Wernicke encephalopathy, cerebellar degeneration, tumors (brainstem, cerebellum, parasellar/chiasmal), trauma.
  • Drug/toxin: anticonvulsants (phenytoin, carbamazepine), lithium, sedatives/hypnotics, alcohol, aminopyridines (excess), toluene.
  • Miscellaneous: oculopalatal tremor (hypertrophic olivary degeneration), thyroid eye disease (rare pendular), superior oblique myokymia (not true nystagmus).

Pathophysiology

• Jerk nystagmus: slow drift due to imbalance (eg, vestibular tone asymmetry or leaky neural integrator) followed by a fast corrective saccade. Alexander’s law: intensity increases in the direction of the fast phase (typical for peripheral vestibular lesions).
• Pendular nystagmus: sinusoidal, no fast phase; arises from instability of oscillatory neural networks (eg, acquired pendular nystagmus in multiple sclerosis or oculopalatal tremor; pendular waveforms also common in INS).
• Waveform attributes (amplitude, frequency, foveation quality) correlate with visual acuity in INS; convergence often dampens INS via vergence-related mechanisms.
• Specific patterns localize lesions: downbeat (craniocervical junction/cerebellar flocculus), upbeat (brainstem), periodic alternating (cerebellar nodulus/uvula), seesaw (parasellar/chiasmal), convergence-retraction “nystagmus” (dorsal midbrain—actually a saccadic disorder).

Epidemiology

• INS prevalence is estimated at ~1 in 1,000 to 1 in 1,500 people in Western populations.
• Afferent visual pathway disorders (eg, albinism) account for a substantial proportion of INS in pediatric cohorts; idiopathic/motor INS is also common [1,2].
• Acquired nystagmus incidence is not well defined; it is frequent in neuro-otology clinics and in multiple sclerosis.

Classification

• By age of onset: infantile (≤6 months) vs acquired (>6 months).
• By waveform: jerk vs pendular.
• By primary plane: horizontal, vertical (downbeat, upbeat), torsional, mixed.
• By behavior:
  • Gaze-evoked vs gaze-independent.
  • Fixation-suppressed (peripheral vestibular) vs not suppressed (central).
  • Periodic alternating (cycles direction every ~90–120 minutes).
  • Latent/manifest latent (emerges or increases with monocular occlusion).
  • Convergence-dampened vs convergence-enhanced.
• By association: with strabismus, head posture, afferent defects.

Symptoms and Signs

• Infantile nystagmus syndrome (INS)

  • Onset in early infancy; horizontal predominant; pendular or jerk with accelerating slow phases.
  • Often improves with convergence and in near fixation; absent oscillopsia.
  • Null zone with abnormal head posture (face turn, chin up/down).
  • Variable visual acuity; associated sensory diagnoses (eg, albinism) reduce acuity further.
  • May have manifest latent component if strabismus is present.

• Sensory nystagmus (infantile)

  • Early onset with decreased visual behavior; fundus, OCT, ERG, or genetic testing often reveal the underlying cause (eg, foveal hypoplasia).

• Spasmus nutans

  • Asymmetric high-frequency, low-amplitude nystagmus with head nodding and torticollis; typically resolves by age 3–4; atypical features warrant imaging.

• Peripheral vestibular nystagmus

  • Acute onset, horizontal-torsional jerk nystagmus; follows Alexander’s law; suppresses with fixation; associated vertigo, nausea, gait unsteadiness; direction fixed relative to head.

• Central nystagmus

  • Pure vertical (downbeat/upbeat) or pure torsional; direction-changing gaze-evoked nystagmus; not suppressed by fixation; often with other neurologic signs (dysarthria, limb ataxia, diplopia).

• Acquired pendular nystagmus

  • Often binocular, multidirectional; disabling oscillopsia; associated with multiple sclerosis or oculopalatal tremor.

• Localizing patterns

  • Downbeat: craniocervical junction/cerebellar disease.
  • Upbeat: medullary/paramedian brainstem lesions.
  • Periodic alternating: cerebellar nodulus/uvula dysfunction or idiopathic.
  • Seesaw: parasellar/chiasmal region.
  • Convergence-retraction: dorsal midbrain (Parinaud) syndrome.

Complications

• Reduced visual acuity and contrast sensitivity; impaired reading speed and visuomotor function.
• Abnormal head posture leading to neck strain and musculoskeletal pain.
• Psychosocial impact and functional limitations (eg, driving eligibility varies by jurisdiction).
• Risk of amblyopia in children with associated sensory disorders or strabismus.
• Falls and disability in patients with severe oscillopsia.

Diagnosis

Clinical evaluation

• History: age at onset; variability with gaze, fixation, convergence, near vs distance; oscillopsia; vertigo; diplopia; neurologic symptoms; developmental history; family history; medications/toxins; birth/trauma history.
• Examination:
  • Characterize waveform, direction, and intensity in primary position and eccentric gazes; apply fixation (Frenzel goggles if needed) and observe Alexander’s law.
  • Assess suppression with fixation and effect of convergence (near target; base-out prism test).
  • Look for null point and abnormal head posture.
  • Ocular exam: visual acuity (preferably with nystagmus acuity function testing when available), refraction (cycloplegic in children), ocular alignment/versions, slit-lamp, intraocular pressure, dilated fundus.
  • Neurologic screen: cranial nerves, cerebellar testing, gait, sensory/motor exam.

Imaging and laboratory testing

• Eye movement recording: video-oculography/electronystagmography to quantify waveform and response to maneuvers [1].
• Optical coherence tomography (OCT): foveal hypoplasia, optic nerve anatomy; helpful in albinism and aniridia [2].
• Visual electrophysiology: electroretinography (ERG) for retinal dystrophies; visual evoked potentials (VEP) for optic pathway dysfunction [2].
• Genetic testing when features suggest syndromic or inherited disease (eg, FRMD7 in X-linked INS; genes for albinism/achromatopsia) [2].
• Neuroimaging (MRI brain ± orbits with contrast):
  • Mandatory in acquired nystagmus, central/localizing patterns (downbeat, upbeat, seesaw), neurologic signs, or atypical/late-onset “spasmus nutans–like” presentations to exclude optic pathway glioma [1,3].
• Vestibular testing (video head impulse, calorics) for suspected peripheral vestibular etiologies.
• Targeted labs when indicated (eg, thiamine deficiency, lithium level, autoimmune/metabolic panels).

Differential diagnosis

Treatment

Medical management

• Correct underlying cause

  • Discontinue or reduce offending drugs/toxins (eg, anticonvulsants, lithium, sedatives) when feasible [4].
  • Thiamine for Wernicke encephalopathy; disease-specific therapy for demyelination, stroke, or tumor.
  • Vestibular neuritis: vestibular rehabilitation; short-term vestibular suppressants may palliate vertigo but can impede central compensation if prolonged [5].

• Optical/rehabilitative interventions

  • Full refractive correction; consider contact lenses (may improve vision and dampen nystagmus in some INS due to enhanced proprioceptive feedback) [2].
  • Filters/tints for photosensitivity in albinism; low-vision services as needed.
  • Prisms:
  • Yoked prisms to shift the image into the null zone and reduce abnormal head posture.
  • Base-out prisms to induce convergence in INS patients with convergence damping [2].

• Pharmacotherapy (largely off-label in the US; discuss risks/benefits and monitor)

  • Baclofen 5–10 mg PO tid (three times daily) for periodic alternating nystagmus; may abolish cycles in responders [1,6].
  • 4-aminopyridine (dalfampridine) 10 mg PO q12h for downbeat nystagmus; improves slow-phase velocity and symptoms in small trials; avoid in seizure history or severe renal impairment (FDA-labeled indication is gait in MS; use here is off-label) [7,8].
  • Clonazepam 0.25–0.5 mg PO bid for downbeat or upbeat nystagmus when aminopyridines are not tolerated [1,6].
  • Gabapentin 300–600 mg PO tid to qid (900–2,400 mg/day) and/or memantine 10 mg PO bid have shown modest improvements in nystagmus intensity and visual function in some infantile and acquired forms; evidence is mixed; both are off-label [1,6,9].
  • Botulinum toxin (retrobulbar or extraocular muscle injections) can transiently reduce oscillations and oscillopsia but often causes ptosis and diplopia; reserve for severe, refractory cases [1,2].

Note: Dosing must be individualized; start low and titrate while monitoring for CNS depression, imbalance, and drug interactions.

Procedural and surgical management

• Strabismus/nystagmus surgery (primarily for INS)

  • Kestenbaum–Anderson procedures (augmented horizontal rectus recessions/resections) to shift the null point toward primary gaze and reduce abnormal head posture; visual acuity may improve modestly through better foveation [2,6].
  • Large symmetric recessions or tenotomy and reattachment (TAR) procedures are used in selected cases to reduce nystagmus intensity [2,6].
  • Concomitant strabismus correction can improve alignment and binocularity.
  • Patient selection: stable, well-defined null point; significant abnormal head posture; realistic expectations regarding acuity gains.

• Neurosurgical/structural interventions

  • Address causative lesions (eg, Chiari I decompression for symptomatic downbeat nystagmus due to cerebellar tonsillar ectopia) [1,6].

Special populations

• Pediatric

  • Early referral (ideally by 2–3 months of age if nystagmus is observed) for comprehensive sensory evaluation, cycloplegic refraction, and imaging/genetic testing when indicated [2,3].
  • Treat amblyopia and refractive errors aggressively; consider prisms for convergence damping.
  • Spasmus nutans: observe if classic and improving; obtain MRI if onset after 1 year, asymmetric/persistent beyond age 3–4, optic disc pallor, or other atypia to exclude optic pathway glioma [3].

• Pregnancy and lactation

  • Limited safety data for gabapentin, memantine, baclofen, and aminopyridines; weigh maternal benefit against fetal/infant risk; prefer nonpharmacologic measures when possible; coordinate with obstetrics [FDA labels and tertiary sources].

• Older adults and medically complex patients

  • Heightened sensitivity to CNS depressants; increased fall risk with sedating agents; simplify regimens and emphasize vestibular/visual rehabilitation.

Prognosis

• INS is typically lifelong but often stable; many patients achieve functional vision with optical correction, accommodations, and, when appropriate, surgery. Visual acuity depends on waveform/foveation and any associated sensory pathology [2,6].
• Acquired nystagmus outcomes depend on etiology. Vestibular causes often improve as compensation develops. Central or degenerative causes may persist; symptom control is variable but possible with targeted therapy and rehabilitation [1,6].

Prevention and Patient Counseling

• Avoid or minimize sedatives, excess alcohol, and medications known to induce nystagmus when alternatives exist.
• Maintain adequate nutrition; promptly treat conditions such as Wernicke encephalopathy.
• Use optimal refractive correction; consider contact lenses or prisms if recommended.
• Coordinate low-vision services, school/work accommodations, and driving evaluations in accordance with state regulations.
• For caregivers: report early ocular motor abnormalities in infants; timely evaluation identifies treatable sensory causes and prevents amblyopia.

When to Seek Immediate Care

• Sudden-onset jerking eye movements with severe vertigo, new double vision, slurred speech, weakness, numbness, or trouble walking.
• New nystagmus after head trauma.
• New oscillopsia or nystagmus with severe headache, neck pain, or altered mental status.
• Any new nystagmus in an adult without a prior history.
• Nystagmus in an infant noted in the first months of life.

Call 911 or go to the emergency department for the first three situations.

References

1. Leigh RJ, Zee DS. The Neurology of Eye Movements, 5th ed. Oxford University Press; 2015.
2. EyeWiki. Infantile Nystagmus. American Academy of Ophthalmology. https://eyewiki.aao.org/Infantile_Nystagmus. Accessed July 24, 2026.
3. AAPOS. Nystagmus. American Association for Pediatric Ophthalmology and Strabismus. https://aapos.org/glossary/nystagmus. Accessed July 24, 2026.
4. StatPearls. Nystagmus. Treasure Island (FL): StatPearls Publishing; updated 2025. https://www.ncbi.nlm.nih.gov/books/NBK470211/
5. Fife TD, Iverson DJ, Lempert T, et al. Practice parameter: therapies for benign paroxysmal positional vertigo (an evidence-based review). Neurology. 2008;70(22):2067-2074. doi:10.1212/01.wnl.0000313378.77444.ac. [Contextual vestibular management]
6. EyeWiki. Downbeat Nystagmus; Periodic Alternating Nystagmus; Nystagmus Overview. American Academy of Ophthalmology. https://eyewiki.aao.org/Downbeat_Nystagmus; https://eyewiki.aao.org/Periodic_Alternating_Nystagmus; https://eyewiki.aao.org/Nystagmus. Accessed July 24, 2026.
7. FDA DailyMed. Dalfampridine (Ampyra) label. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b7bde83-2e06-4b50-9b0b-3b8c60a1b11d. Accessed July 24, 2026.
8. Kalla R, Muroi A, Schmitt N, et al. 4-Aminopyridine for the treatment of downbeat nystagmus: a randomised, double-masked, placebo-controlled trial. J Neurol Neurosurg Psychiatry. 2011;82(11):1254-1257. doi:10.1136/jnnp.2010.235739.
9. Thurtell MJ, Joshi AC, Leone AC, et al. Crossover trial of gabapentin and memantine as treatment for acquired nystagmus. Neurology. 2010;74(11): 1–8.
10. Maconachie G, Gottlob I. Nystagmus: state of the art. Clin Exp Optom. 2019;102(6):497-503. doi:10.1111/cxo.12922.

This article is for informational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified eye care professional about your specific condition. If you have sudden vision loss, severe eye pain, or an eye injury, seek emergency care immediately.